MiniMed (MMED) Q1 2027 earnings review
U.S. Rebound and Pipeline Execution Drive Return to Breakeven
MiniMed delivered a dramatic turnaround in Q1 FY27, reversing a streak of heavy losses to achieve breakeven Net Income ($0) on the back of a 17% revenue surge to $843M. The standout story is the U.S. market, which snapped out of a growth stall (1.5% in Q4) to an accelerating 13.1% YoY gain, driven by the MiniMed Flex launch. Management raised FY27 organic growth guidance to 10.5%. While 4-6% of the headline revenue growth was an illusion of an extra week in the calendar, the underlying low-double-digit growth and rapid execution of the product pipeline confirm a highly constructive setup for the year.
🐂 Bull Case
The Q4 'buyers strike' as patients awaited new technology is officially over. The MiniMed Flex launch drove U.S. revenue up 13.1% and pushed New Pumps Sold (NPS) growth over 20% YoY in the region.
Operating income flipped from a $13M loss a year ago to a $5M profit. The company completely erased the $183M net loss posted just one quarter ago, proving operating leverage exists as volume returns.
🐻 Bear Case
Cost of products sold jumped 20% YoY, outpacing revenue growth. This compressed gross margins slightly, suggesting new product ramps or capacity expansions are temporarily weighing on unit economics.
The reported 16.6% global growth includes a 4-6% benefit from a 53-week calendar. Stripping this out, growth is closer to 11-12%—still healthy, but less explosive than the headline implies.
⚖️ Verdict: 🟢
Bullish. The U.S. business is rapidly digesting the Flex launch, the pipeline is printing regulatory milestones ahead of schedule, and the bottom line is finally stabilizing. The slight gross margin compression is a worthwhile trade for this level of ecosystem expansion.
Key Themes
MiniMed Flex Unlocks U.S. Stagnation
Accelerating. The U.S. market went from being a major laggard in FY26 Q4 (1.5% growth) to the primary catalyst in Q1 FY27 (13.1% growth). Management explicitly linked this to the MiniMed Flex launch and its expanded Medicare coverage. With U.S. New Pumps Sold up over 20%, the system is succeeding in capturing competitive conversions and pulling patients off the sidelines.
CGM Attachment Becomes the Growth Engine
Stable and compounding. Continuous Glucose Monitoring (CGM) revenue surged 19.9% YoY to $431M, making it by far the largest product category (over 50% of total sales). The worldwide CGM attachment rate climbed 100 basis points sequentially to 69%. The launch of the Instinct sensor (made by Abbott) in Europe is driving high-margin recurring revenue.
Aggressive Pipeline Execution
The company is hitting product milestones ahead of schedule. The MiniMed Fit patch pump was submitted to the FDA ahead of its Fall target (summer 2027 launch expected), MiniMed Flex secured a CE Mark ahead of the year-end target, and the Vivera fully-closed loop U.S. pivotal trial completed enrollment. This cadence derisks the forward-looking revenue projections by ensuring a continuous refresh cycle across all geographies.
Gross Margin Compression
Decelerating. Despite the massive revenue beat, Gross Margin compressed from 56.5% in 26Q1 to 55.1% in 27Q1. Cost of products sold increased 20.3% ($378M vs $314M), significantly outpacing the 16.6% revenue growth. If MiniMed cannot optimize manufacturing costs for new products like Flex and Simplera, the bottom-line recovery will hit a ceiling.
Calendar Mirage Inflates Topline
Management noted a 4-6% benefit to worldwide net sales simply due to an extra week in the 52-53 week fiscal calendar. This means the 'reported' 16.6% growth overstates actual demand velocity. Investors must monitor Q2 to ensure the low-double-digit baseline organically sustains itself when the calendar normalizes.
Other KPIs
Accelerating YoY. Up 7.7% compared to the prior year. While sequentially lower than the 42,000 sold in 26Q4, the YoY growth is a critical indicator of ecosystem health, fueled heavily by >20% U.S. NPS growth following the Flex launch.
Improving. Combined R&D ($115M) and SG&A ($312M) grew only 4.6% YoY against a 16.6% revenue expansion. R&D actually declined YoY from $125M to $115M. This strict expense control is the primary reason the company was able to cross into positive operating income ($5M) despite the gross margin pressure.
Guidance
Accelerating. Raised from prior guidance of ~10%. This figure includes a 1.0-1.5% benefit from the Q1 extra week, implying underlying organic growth of roughly 9-9.5%. This represents a meaningful acceleration from the 8.0% organic growth reported for full-year FY26.
Stable. Reaffirmed from prior guidance. Achieving this will require careful navigation of the current COGS inflation and successful scaling of the Simplera manufacturing capacity to offset the initial launch costs of MiniMed Flex and Instinct.
Key Questions
Gross Margin Trajectory
Cost of products sold rose 20% YoY, outpacing sales. How much of this is transient launch/capacity expansion costs for Simplera and Flex, and when do you expect gross margins to inflect positively?
Abbott Partnership Economics
With the Instinct sensor (made by Abbott) now launching in Europe, how does the margin profile of third-party integrated sensors compare to proprietary sensors, and how does it impact the path to your 16% EBITDA target?
U.S. Pump Growth Composition
U.S. New Pumps Sold grew over 20%. Can you break down how much of this was backlog fulfillment from Q4 versus entirely new competitive conversions driving structural market share gains?
Vivera Trial Insights
With the Vivera fully-closed loop U.S. pivotal trial enrollment complete for both Type 1 and Type 2, what are the early indicators regarding patient retention and algorithm engagement compared to current iterations?